NIH mandates diverse clinical trials, funds community outreach to boost underrepresented participati

What it does

This bill requires the NIH to mandate that clinical trial sponsors set clear, measurable goals for recruiting and retaining participants from diverse racial, ethnic, age, and sex groups that reflect either the disease prevalence in those groups or the general U.S. population. Sponsors must submit detailed plans showing how they'll achieve these goals, reduce participation burdens (via telehealth, home visits, flexible scheduling), and train researchers on diversity and health equity. The bill also funds a national public awareness campaign and grants to nonprofits to increase clinical trial participation among underrepresented groups, with a requirement that the NIH publish trial diversity data annually.

Why we flagged it

The bill's core mechanism is a regulatory requirement imposed on NIH-funded clinical trial sponsors to achieve demographic diversity in recruitment and retention, backed by reporting, remediation, and public transparency. It is a public-health equity measure, not a market intervention or appropriation.

What the text implies

• Sponsors of ongoing trials as of enactment are exempt (subsection f), creating a two-tier system where new trials face stricter diversity requirements than existing ones, potentially delaying new drug/device approvals relative to legacy trials.
• The bill requires NIH to study modernization of human-subject reimbursement rules and anti-kickback safe harbors (section 3), which may lead to future regulatory changes allowing higher participant compensation or broader recruitment incentives—outcomes not directly mandated here but flagged for study.
• Publication of trial diversity goals and remediation plans on NIH website (subsections d and e) creates public accountability but may also expose proprietary trial design details or competitive information if not carefully redacted.
• The $10M/year grant program (section 4(f)) to nonprofits and community organizations for outreach may create dependency on federal funding for sustained diversity recruitment infrastructure, with no guarantee of continuation beyond 2030.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary citizens in underrepresented racial, ethnic, age, and sex groups gain concrete benefits: reduced participation barriers (telehealth, flexible hours, home visits), increased awareness of trial opportunities, and assurance that drugs and devices are tested on populations that reflect them. The bill also improves scientific validity by ensuring trial results apply more broadly. Compliance costs fall on sponsors and researchers, not citizens.

Who stands to gain

• nonprofit community-based organizations and faith communities (grants for outreach)
• institutions of higher education (grants for outreach)
• community pharmacies (grants for outreach)
• clinical trial sponsors (reduced liability risk if they meet diversity goals)

Named in the bill

National Institutes of Health (NIH), Secretary of Health and Human Services, Food and Drug Administration (FDA), Comptroller General of the United States, Health Resources and Services Administration (HRSA), Office on Minority Health, Centers for Disease Control and Prevention (CDC), National Advisory Council on Minority Health and Health Disparities, Advisory Committee on Research on Women's Health, Tribal Health Research Coordinating Committee

Where it stands

11 cosponsors: 10 Democrats, 1 Republicans.

• Dec 18, 2025 — Introduced · Congress.gov: “Introduced in House”
• Dec 18, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

2 lobbying clients named this bill on 2 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $630,000 in lobbying spend. A filing names 24 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 41% of bills with at least one filing.

Robin Kelly, the sponsor, reported $539,150 in PAC receipts in the 2026 cycle.

• Blood Cancer United (fka the Leukemia & Lymphoma Society) — $590,000 on 1 filing
• Patient Access Network Foundation — $40,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.